Rapid Rx Quiz: Dangerous Drug Combinations

Mary L. Windle, PharmD


March 13, 2023

Antiarrhythmic agents and DOACs are often coadministered to decrease stroke risk secondary to arrhythmias. Amiodarone increases bleeding risk in patients taking rivaroxaban by inhibiting hepatic cytochrome P450 (CYP) 3A4 metabolism. When creatinine clearance is slightly low, rivaroxaban concentrations increase about 1.86-fold when combined with amiodarone, leading to the increased risk for bleeding. Phenytoin decreases levels of rivaroxaban by inducing CYP3A4 metabolism. Procainamide and dofetilide do not affect CYP3A4 metabolism.

Learn more about amiodarone.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.